Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Liabilities (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 55.58% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Sep 2025, down 55.58%, and an annual FY2024 reading of $3.3 million, down 90.68% over the prior year.
  • Other Non-Current Liabilities was $1.8 million for Q3 2025 at Atara Biotherapeutics, down from $40.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $40.8 million in Q2 2025 and bottomed at $616000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 4 years is $8.6 million, with a median of $4.8 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities plummeted 90.68% in 2024, then soared 878.95% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $5.6 million in 2022, then surged by 530.41% to $35.1 million in 2023, then tumbled by 90.68% to $3.3 million in 2024, then plummeted by 46.07% to $1.8 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ATRA at $1.8 million in Q3 2025, $40.8 million in Q2 2025, and $3.1 million in Q1 2025.